WELL HEALTH TECHS

WELL Health reported a 12% revenue increase in Q2 2026 to CAD 400 million (normalized CAD 395.6 million) and normalized adjusted EBITDA of CAD 43.3 million (+8%). After a strong June and gains in technology and diagnostics, management raised the 2026 revenue guidance to CAD 1.58–1.65 billion and the EBITDA range to CAD 185–195 million. Operational growth was supported by acquisitions such as Ontario Imaging Diagnostics, while net debt rose to CAD 628.7 million. The stock traded slightly lower in after-hours despite improved margins and the announced listing of WELLSTAR on the TSX Venture. » Más en de.investing.com

WELL Health reported record results for FY2025 with an adjusted EBITDA of $203.7m and adjusted net income of $126.5m, with EPS significantly exceeding expectations. The company said it is reviewing strategic options for its U.S. health businesses (including Circle Medical, CRH, wisp) and will focus more on its Canadian clinic network and the technology platforms WELLSTAR and HEALWELL AI. WELL Canada showed accelerated revenue and EBITDA growth, M&A activity was stepped up, and management forecasts 2026 revenue of $1.55–1.65bn and adjusted EBITDA of $175–185m. » Más en de.investing.com

WELL Health reported Q4 EPS of CAD 0.20, well above the estimate of CAD 0.1035, while revenue of CAD 384.77 million came in just under expectations of CAD 385.23 million. For fiscal 2025 the company posted revenue of CAD 1.4 billion (+52%) and an adjusted EBITDA margin of 14.5%. Management highlights growth of the WELLSTAR and HEALWELL AI technology platforms and an active M&A strategy, and issues positive EPS and revenue guidance for 2026. The stock fell about 2.4% in pre-market trading to CAD 4.11 and is trading near its 52-week low, indicating mixed investor reaction. » Más en de.investing.com